nach oben

Drugs & Aging

Erschienen in:

01.07.2011 | Review Article

Combination Therapy for Alzheimer’s Disease

verfasst von: Dr Laxeshkumar Patel, MD, George T. Grossberg

Erschienen in: Drugs & Aging | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Alzheimer’s disease (AD) is a progressive, degenerative brain disease. The mainstay of current management of patients with AD involves drugs that provide symptomatic therapy. Two classes of medications have been approved by the US FDA for the treatment of AD: the cholinesterase inhibitors (ChEIs), which include galantamine and rivastigmine (both approved for use in mild to moderate AD) and donepezil (approved for use in mild to severe AD); and the non-competitive NMDA receptor antagonist memantine (approved for use in moderate to severe AD). The European and Asian regulatory bodies have also approved ChEIs as monotherapy in mild to moderate AD. Future research directions are mostly focusing on disease modification and prevention.

This review covers key studies of the efficacy, safety and tolerability of combination therapy in AD, defined as a combination of the NMDA receptor antagonist memantine with any of the ChEIs (donepezil, galantamine or rivastigmine) for the treatment of AD. Relevant studies were identified via a PubMed search. This review shows that combination therapy for AD seems to be safe, well tolerated and may represent the current gold standard for treatment of moderate to severe AD and possibly mild to moderate AD as well.

Cummings JL, Cole G. Alzheimer disease. JAMA 2002; 287: 2335–8PubMedCrossRef

Ownby RL, Crocco E, Acevedo A, et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and meta-regression analysis. Arch Gen Psychiatry 2006; 63: 530–8PubMedCrossRef

Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2003; 15: 346–53PubMedCrossRef

Burns A, Iliffe S. Alzheimer’s disease. BMJ 2009; 338: b158PubMedCrossRef

Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer’s disease. Science 2006; 314: 781–4PubMedCrossRef

Folwell J, Cowan CM, Ubhi KK, et al. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer’s disease. Exp Neurol 2010 Jun; 223(2): 401–9PubMedCrossRef

Winblad B. Socio-economic perspectives of dementia and cost-effectiveness of treatment. 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; 2002 Apr 3–6; Geneva

Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119–22PubMedCrossRef

Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–8PubMedCrossRef

10.

Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ 2000; 321: 1445–9PubMedCrossRef

11.

Winblad B, Wimo A, Engedal K, et al. 3-Year study of donepezil therapy in Alzheimer’s disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21: 353–63PubMedCrossRef

12.

Black S, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69: 459–69PubMedCrossRef

13.

Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057–65PubMedCrossRef

14.

Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–20PubMedCrossRef

15.

Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004; 61: 1852–6PubMedCrossRef

16.

Ritchie CW, Ames D, Clayton T, et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004 Jul–Aug; 12(4): 358–69PubMed

17.

Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3(2): 211–25PubMed

18.

Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135–46PubMedCrossRef

19.

Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41PubMedCrossRef

20.

Dysken MW, Mendels J, LeWitt P, et al. Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc 1992; 40: 503–6PubMed

21.

Laake K, Oeksengaard AR. D-cycloserine for Alzheimer’s disease. Cochrane Database Syst Rev 2002; 2: CD003153PubMed

22.

Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291(3): 317–24PubMedCrossRef

23.

van Dyck CH, Schmitt FA, Olin JT. Memantine MEMMD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry 2006; 14(5): 428–37PubMedCrossRef

24.

Rountree SD, Chan W, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009; 1: 7PubMedCrossRef

25.

Atri A, Shaughnessy LW, Locascio JJ, et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008 Jul–Sep; 22(3): 209–21PubMedCrossRef

26.

Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008 Feb; 5(1): 83–9PubMedCrossRef

27.

Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized controlled trial. Am J Geriatr Psychiatry 2006; 14: 704–15PubMedCrossRef

28.

Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomized, doubleblind, placebo-controlled 6-month study. J Alzheimers Dis 2007; 11: 471–9PubMed

29.

Hartmann S, Möbius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003; 18: 81–5PubMedCrossRef

30.

Yao C, Raoufinia A, Gold M, et al. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol 2005; 45: 519–28PubMedCrossRef

31.

Shua-Haim JR, Smith J, Pass M, et al. Safety, tolerability, and caregiver’s impressions of combination therapy with galantamine and memantine for the treatment of Alzheimer’s disease [abstract P1-392]. Poster presented at the American Psychiatric Association 2004 Annual Meeting; 2004 Jul 17–22; Philadelphia (PA)

32.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

33.

Ramaswamy K. Safety of galantamine-memantine combination treatment for mild to moderate Alzheimer’s disease. Poster presented at the 57th Institute on Psychiatric Services; 2005 Oct 5–9; San Diego (CA)

34.

Olin JT, Bhatnagar V, Reyes P, et al. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 2010 Apr; 25(4): 419–26PubMedCrossRef

35.

Farlow MR, Alva G, Meng X, et al. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis. Curr Med Res Opin 2010 Feb; 26(2): 263–9PubMedCrossRef

36.

Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009 Jun; 80(6): 600–7PubMedCrossRef

37.

Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18Suppl. 1: S23–32PubMedCrossRef

38.

Reisberg B, Doody R, Stöffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006 Jan; 63(1): 49–54PubMedCrossRef

39.

Mohs RC, Kawas C, Carrillo MC. Optimal design of clinical trials for drugs designed to slow the course of Alzheimer’s disease. Alzheimer Dement 2006; 2: 131–9CrossRef

40.

Martinez-Coria H, Green KN, Billings LM, et al. Memantine improves cognition and reduces Alzheimer’s-like neuropathology in transgenic mice. Am J Pathol 2010 Feb; 176(2): 870–80PubMedCrossRef

Titel: Combination Therapy for Alzheimer’s Disease
verfasst von: Dr Laxeshkumar Patel, MD
George T. Grossberg
Publikationsdatum: 01.07.2011
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 7/2011
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/11591860-000000000-00000

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2011

Polypharmacy in the Elderly

Ketorolac 0.45% Ophthalmic Solution

Clinical, Demographic and Functional Characteristics Associated with Pharmacotherapy for Heart Failure in Older Home Care Clients

Variation Over Time in the Association between Polypharmacy and Mortality in the Older Population

Elderly Patients with Community-Acquired Pneumonia